T1	Participants 115 135	early breast cancer:
T2	Participants 281 287	women.
T3	Participants 502 528	1,614 consecutive patients
T4	Participants 621 693	postmenopausal women with early hormone receptor-positive breast cancer.
T5	Participants 1268 1296	Patients receiving tamoxifen
